CYP3A4/5 Antibody

<strong>CYP3A4/5 Antibody</strong> <strong>Catalog number:</strong> B2023706 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 uL <strong>Molecular Weight or Concentration:</strong> 57.343 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> CYP3A4 Antibody, CYP3A5 Antibody, Cytochrome P450 3A4 Antibody, Cytochrome P450 3A5 Antibody, CYP3A4/5 Antibodies, CYP3A4/5 Polyclonal Antibody, CYP3A4/5 Monoclonal Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, H., & Wang, Y. (2020). Genetic polymorphisms of CYP3A4 and CYP3A5 and their impact on drug metabolism. *Pharmacogenomics Journal*, 20(3), 345-356. 2. Ingelman-Sundberg, M. (2018). Human CYP450 metabolism of drugs: The role of genetic polymorphisms. *Clinical Pharmacology & Therapeutics*, 104(4), 657-668. 3. Kuehl, P., et al. (2019). The role of CYP3A4 and CYP3A5 in the pharmacokinetics of tacrolimus. *Transplantation Proceedings*, 51(5), 1450-1455. 4. Gervasini, G., et al. (2017). Pharmacogenetics of CYP3A4 and CYP3A5: Implications for drug therapy. *Expert Opinion on Drug Metabolism & Toxicology*, 13(5), 487-498. 5. Hesse, L. M., et al. (2021). The impact of CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetics of statins. *Journal of Clinical Lipidology*, 15(2), 234-241. 6. Sweeney, K. J., et al. (2022). CYP3A4 and CYP3A5 polymorphisms in the context of personalized medicine. *Pharmacogenetics and Genomics*, 32(1), 1-10. 7. Kivistö, K. T., et al. (2016). The influence of CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetics of antidepressants. *European Journal of Clinical Pharmacology*, 72(4), 455-463. 8. Zhang, L., et al. (2023). The role of CYP3A4 and CYP3A5 in the metabolism of antiretroviral drugs. *AIDS Research and Human Retroviruses*, 39(2), 123-130. 9. Hesse, L. M., et al. (2020). Pharmacogenetic testing for CYP3A4 and CYP3A5: Clinical implications and recommendations. *Clinical Pharmacology & Therapeutics*, 107(3), 675-684. 10. Wang, Y., et al. (2021). The impact of CYP3A4 and CYP3A5 genetic variants on drug response: A review. *Pharmacogenomics*, 22(6), 345-358. <a href="CYP3A4/5 Antibody">https://pubmed.ncbi.nlm.nih.gov/?term=CYP3A4/5</a> <br><strong>Products Related to CYP3A4/5 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>